Post by
SteveMcM1 on Nov 22, 2015 1:40am
The More I Search, the More Mind-Boggling the Adcom's Decis
ion to vote against MCNA becomes. A quote from the FDA:
"As for FDA, although there may be problems with the clinical trials intended to support a sponsors original proposed indication, if a compound has activity its incumbent on us to work with the sponsor to try to get the drug to the public for areas of high unmet medical need, Office of Hematology and Oncology Products Director Richard Pazdur said in an interview."
Here is what I find extremely interesting in relation to the above quote. In 2015, the FDA approved Farydak to treat 3rd line plus multiple myeloma patients, after the Adcom voted against its approval.
I currently work in pharmaceutical forecasting for a company who is a major player in the multiple myeloma space. There is a MUCH higher unmet need in the bladder cancer space than in the multiple myeloma space; the comparisons are not even close. At the time the FDA went against the Adcom’s recommendation and approved Farydak, the following treatments were available and had long-standing successful histories in treating multiple myeloma:
Velcade - frontline therapy
Revlimid - relapse/refractory
Pomalyst - third line plus
Kyprolis - third line plus
Thalomid - very rarely used but available
-------------------------------------------------
Daratumimab - phase III clinical trials were ongoing in 2015
Elotuzimab - phase III clinical trials were ongoing in 2015
My point of posting this is just to show that Farydak was able to get approved after an FDA adcom rejection, with all of the above treatments available!! There has been nothing in the bladder cancer space since God-awful Valstar in 1998!!! This defines high unmet medical need!!
Comment by
Brouwie on Nov 22, 2015 2:23am
Good read, '' If a drug has activity, its incumbent on us to work with the sponsor to try to make it available for patients with high unmet need, OHOP Director Pazdur said.''
Comment by
rgonlyfactspls on Nov 22, 2015 11:17am
thathurt...that is interesting. However you left out one small detail...the Company you are referring too (unless I missed it in all the cryptic text). Pls provide and possibly include link. Thank you.
Comment by
DamnYankees on Nov 22, 2015 12:45pm
RGF, you might have misread Hurt. I did not interpret his message that way, although I think I see where you got tripped up. Worth reading again. On a board that has too many " The Government has a tracking device planted in me" types, don't discount the few intellects that bother posting here. Whether you disagree with them or not.
Comment by
DamnYankees on Nov 22, 2015 2:44pm
I had many of these rabbit hole conversations in college. Very intelligent conversations, with guys who would up being multi multi millionaires of different sorts later In life. The difference is we were smoking Turkish hashish and didn't have human lives hinging on our senseless intellectual bender. I get the rabbit hole analogy.
Comment by
rgonlyfactspls on Nov 22, 2015 1:23pm
DamnYankees... Just know I asked thathurt a very simple request... "name of company". If post was the truth, easy enough to do, and can't believe any concerns as all now history if I recall. Maybe later will un-ignore and re-read the post(s). Thanks for the fyi. rg
Comment by
DamnYankees on Nov 22, 2015 11:41am
Correction -Admittedly not admiringly and I am unclear whether Ipsen has direct US representation for their oncology lineup. I know a product that they can start with though if prepared to provide the necessary horsepower to get MCNA it's just approval